InVasc Therapeutics is a Tucker, Georgia-based biopharmaceutical company developing drugs to mitigate risks associated with cardiometabolic diseases. Its lead program, INV-144, targets slowing the progression of chronic kidney disease in hypertensive diabetic patients. The company plans to file an IND for INV-144 later this year and will use the financing primarily to advance a Phase II trial. InVasc recently received an SBIR grant from the NIH. Management announced a new board that includes Daniele Cardoso of Trois I, Larry Dillaha, Bill Schaeffer, and CEO William Johnston. The company has completed an initial closing of its first financing round to support these activities. InVasc Therapeutics develops small-molecule and biologically targeted drugs to reduce risks from cardiometabolic diseases. Its programs include derivatives of alpha lipoic acid aimed at preventing and treating hypertension and stroke, and inhibitors of myeloperoxidase for acute vascular or inflammatory events. The company is advancing a candidate, INV-144, intended to reduce proteinuria in hypertensive diabetic patients and plans to file an IND later in the year. Financially, InVasc has been awarded two NIH SBIR Phase 1 grants totaling nearly $400,000 to support its R&D. The funding supports ongoing discovery and preclinical development activities rather than commercial operations. The company is based in Tucker, Georgia.

Total raised

$4M

Funding rounds

2

Latest round

Equity

Latest activity

Jul 2010